Saturday 17 October 2026 Export VNRX’s income statement to Excel — free account

VolitionRX Limited

VolitionRX Limited’s revenue for fiscal 2025 (year ended December 2025) was $1.7 million, up 40.0% from fiscal 2024. In the quarter to June 2026, revenue fell 1.97%, EPS grew 29.2%, free cash flow grew 18.6% and total debt rose 7.56%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

0.18 0.01 −5.26%

Follow VNRX

Alert me

Market cap: $5.3M
P/E: 0.0×
Fwd P/E: −0.8×
Dividend yield: —
F-score: 2/9
Altman Z: −62.83
Beneish M: −4.07
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.01

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 5.25

Revenue 2.46

Net Income (25.73)

Free Cash Flow (19.58)

Net Debt 8.20

Current Ratio 0.30

Debt/Equity (0.33)

P/E ratio 0.00

Fwd P/E (0.77)

P/S ratio 0.67

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 55.97%

Next Y EPS Growth 62.15%

Next Y revenue growth 57.69%

Next 5Y EPS Growth 57.20%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.11%

10-year low 10-year high

EV/Sales against its own 10 years 0.11%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	21	3	1	3
Receivables	0	0	0	0
Inventory	—	—	—	—
Other	0	0	0	0
	22	4	2	4

	2023	2024	2025	Q'26
Payables	3	3	3	4
ST’ Debt	1	1	3	4
Other	0	0	1	2
	9	8	12	13

Compound Annual Growth %

	10y	5y	3y
Sales	—	164.28%	77.98%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Sep	Dec	Year
’26	1	—	—	—
’25	0	1	0	2
’24	0	0	0	1
’23	0	0	0	1
’22	0	0	0	0
’21	0	0	0	0
’20	0	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(5)	(5)	—	—	—
’25	(4)	(6)	(4)	(5)	(20)
’24	(8)	(7)	(5)	(5)	(26)
’23	(9)	(7)	(8)	6	(18)
’22	4	(6)	(7)	(6)	(15)
’21	(6)	(5)	(5)	(4)	(21)
’20	(5)	(4)	(4)	(3)	(16)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(5)	(5)	—	—	—
’25	(4)	(6)	(4)	(6)	(20)
’24	(8)	(7)	(6)	(6)	(26)
’23	(9)	(8)	(9)	6	(19)
’22	3	(7)	(7)	(6)	(17)
’21	(7)	(6)	(5)	(5)	(22)
’20	(5)	(5)	(4)	(4)	(18)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.97)	(0.85)	—	—	—
’25	(1.20)	(1.20)	(1.00)	(1.00)	(4.40)
’24	(2.00)	(1.60)	(1.40)	(1.20)	(6.20)
’23	(3.00)	(2.80)	(2.20)	(2.20)	(10.00)
’22	(2.80)	(2.80)	(2.80)	(2.60)	(11.00)
’21	(2.40)	(2.00)	(2.60)	(3.00)	(10.20)
’20	(2.80)	(2.40)	(1.80)	(2.20)	(9.00)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	61.00	41.60	28.80	37.80	44.40	58.20	26.20	11.00	8.60	4.40	Analyst estimates 2026–2028 Powerpack
	High	117.20	109.00	80.00	136.80	104.00	133.40	66.00	54.00	24.60	18.80
People
People	Employees	22	37	44	50	65	83	104	110	85	75
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.02
Income, $m
Income, $m	Revenue	—	—	—	0	0	0	0	1	1	2
	Gross margin, %	0.00	0.00	0.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	(12)	(15)	(18)	(16)	(20)	(27)	(31)	(36)	(27)	(24)
	EBT margin, %	0.00	0.00	0.00	(94,146.78)	(152,233.58)	(29,988.67)	(9,986.46)	(4,601.72)	(2,209.81)	(1,360.62)
	Net income	(12)	(15)	(18)	(16)	(20)	(27)	(31)	(36)	(27)	(24)
	Depreciation	0	1	1	1	1	1	1	1	1	3
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.01	0.01	0.03	0.11	0.22	0.29	0.32
	Earnings	(10.40)	(11.20)	(11.40)	(8.20)	(9.00)	(10.20)	(11.00)	(10.00)	(6.20)	(4.40)
	Cash flow	(7.69)	(9.24)	(9.39)	(6.50)	(7.27)	(7.92)	(5.52)	(5.07)	(5.98)	(3.68)
	Capex	(0.36)	(1.08)	(0.19)	(0.26)	(0.73)	(0.37)	(0.57)	(0.30)	(0.13)	(0.02)
	Free cash flow	(8.05)	(10.32)	(9.58)	(6.76)	(8.00)	(8.29)	(6.09)	(5.38)	(6.12)	(3.70)
	Book value	18.37	7.55	7.74	7.25	7.20	6.73	(1.13)	(2.45)	(6.03)	(6.66)
	Shares, m	1	1	2	2	2	3	3	4	4	5
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	2,649.26	13,144.72	1,837.11	431.74	96.47	42.09	16.08
	P/B	—	—	—	13.08	10.81	9.33	0.00	0.00	0.00	0.00
	EV/Sales	—	—	—	2,456.46	11,995.87	1,648.20	410.25	76.48	43.61	21.73
	EV/FCF	—	—	—	(12.94)	(8.85)	(6.78)	(7.44)	(3.09)	(2.03)	(1.87)
Cash, $m
Cash, $m	Operating cash flow	(9)	(12)	(15)	(13)	(16)	(21)	(15)	(18)	(26)	(20)
	Capex	0	(1)	0	(1)	(2)	(1)	(2)	(1)	(1)	0
	Free cash flow	(9)	(14)	(15)	(13)	(18)	(22)	(17)	(19)	(26)	(20)
Balance, $m
Balance, $m	Working capital	20	8	12	14	14	15	(5)	13	(4)	(10)
	Total debt	1	3	3	3	4	4	4	5	5	11
	Net debt	(20)	(7)	(10)	(14)	(15)	(17)	(7)	(15)	2	10
	Shareholders’ equity	21	10	12	14	16	18	(3)	(9)	(26)	(36)
Returns, %
Returns, %	ROA	(73.39)	(75.05)	(112.16)	(83.03)	(85.80)	(99.98)	(132.22)	(152.75)	(144.41)	(286.58)
	ROIC	(915.17)	(371.41)	(609.86)	(1,468.05)	(1,476.85)	(2,457.42)	0.00	0.00	0.00	0.00
	ROE	(87.48)	(94.88)	(162.99)	(122.24)	(133.49)	(157.66)	(414.78)	596.65	154.90	75.71

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
WOK WORK Medical Technology Group LTD	$6.0M	—	—	—	—	−948.94% (below 0%: shrinking)	—	—	Compare
AMIX Autonomix Medical, Inc.	$5.7M	— (loss-making)	—	—	n/m	−36.10% (below 0%: shrinking)	—	0.00%	Compare
NVNO enVVeno Medical Corporation	$5.5M	— (loss-making)	— (loss-making)	+0.32% (above 0%: growing)	n/m	+4.60% (above 0%: growing)	0.00%	0.00%	Compare
CODX Co-Diagnostics, Inc.	$5.3M	— (loss-making)	— (loss-making)	+1.96% (above 0%: growing)	n/m	+17.47% (above 0%: growing)	72.73%	(3,733.17%)	Compare
TBIO Telesis Bio Inc.	$5.3M	— (loss-making)	— (loss-making)	−61.79% (below 0%: shrinking)	n/m	−17.96% (below 0%: shrinking)	64.43%	(349.74%)	Compare
VNRX VolitionRX Limited	$5.3M	— (loss-making)	— (loss-making)	−1.97% (below 0%: shrinking)	n/m	+18.58% (above 0%: growing)	100.00%	(1,042.39%)
TRIB Trinity Biotech PLC	$5.1M	— (loss-making)	— (loss-making)	+43.28% (above 0%: growing)	n/m	+75.24% (above 0%: growing)	35.43%	(24.53%)	Compare
VVOS Vivos Therapeutics, Inc.	$4.8M	— (loss-making)	— (loss-making)	+34.90% (above 0%: growing)	n/m	+16.44% (above 0%: growing)	57.31%	(93.63%)	Compare
INBS Intelligent Bio Solutions Inc.	$4.8M	— (loss-making)	5.4×	+51.10% (above 0%: growing)	n/m	−31.59% (below 0%: shrinking)	43.23%	(360.19%)	Compare
Median of peers	$5.3M	—	—	+18.43%	—	−6.68%	50.27%	(93.63%)

All 149 Medical Devices stocks →

VolitionRX Limited (VNRX) key facts

Strength: VolitionRX Limited’s revenue for fiscal 2025 (year ended December 2025) was $1.7 million, up 40.0% from fiscal 2024.
VolitionRX Limited (VNRX) is a Medical Devices company in the Healthcare sector, listed on NYSE American.
As of October 16, 2026, VNRX traded at $0.18, a market capitalization of $5.3 million.
Return on equity was 75.7% and debt-to-equity -0.33.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −62.83 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.